Catalyst
Slingshot members are tracking this event:
Imprimis Pharmaceuticals Registers its Texas Facility with the FDA as an Outsourcing Facility
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMY | Community voting in process | |||||
Additional Information
Mark L. Baum, CEO of Imprimis, stated, "This is an important milestone for our growing company. We believe transitioning our Dropless Therapy® injectable formulations to an outsourcing facility environment is good for our number one constituent – our patients. And if it is good for our patients, it is good for Imprimis and its shareholders. Importantly, operating as a 503B outsourcing facility should create new revenue opportunities by simplifying the ordering process with existing and new potential customers, including hospitals, group purchasing organizations, and surgery centers, that desire, or in some cases, require purchasing from an FDA-registered outsourcing facility. According to internal research and an April 2015 third party market research report, adoption of our core ophthalmology formulations is expected to increase as a result of moving to an outsourcing facility and once customers are no longer required to provide patient-specific prescriptions."
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 12, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Outsourcing Facility
